viewImugene Ltd

Imugene director Charles Walker makes another share purchase

The company is developing a range of treatments to activate the immune system of cancer patients.

Imugene Ltd - Imugene non-executive director Charles Walker makes another share purchase
Walker now holds 28,523,210 shares in the company

Imugene Limited (ASX:IMU) non-executive director Charles Walker has made an indirect purchase of 172,500 shares in the company.

The purchase for 16.5 cents per share by a director related entity brings Walker’s total securities to 28,523,210 (direct and indirect holdings).

Managing director and chief executive officer Leslie Chong also made two seperate share purchases; 400,000 shares at 2.2 cents per share and 475,240 at 1.8 cents per share.

She now holds 4,387,124 shares and 77,098,765 options in the company.

Immuno-oncology treatments

Imugene is focused on developing immuno-oncology treatments CF33 and PD1-Vaxx in first-in-human studies.

CF33 has been shown to efficiently shrink injected tumours and distant non-injected tumours in human triple-negative breast cancer, colon cancer, ovarian cancer xenograft models in mice without adverse effects.

The company’s PD1-Vaxx is a B-cell immunotherapy, peptide cancer vaccine designed to treat tumours such as lung cancer and will be trialled on patients in 2020.

The company is continuing enrolment of its HER-Vaxx phase-2 study, which is a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer with Phase 2 studies underway.

Quick facts: Imugene Ltd

Price: 0.046 AUD

Market: ASX
Market Cap: $206.55 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...



Imugene gets green light to start phase-1 clinical trial of new cancer...

Imugene Ltd's (ASX:IMU) Leslie Chong speaks to Proactive's Andrew Scott following the news it's received a second Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx. Ethics approval is confirmation that Imugene...

on 20/7/20

2 min read